Literature DB >> 28400314

PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity.

Hagay Kohay1, Can Sarisozen2, Rupa Sawant3, Aditi Jhaveri4, Vladimir P Torchilin5, Yael G Mishael6.   

Abstract

A novel drug delivery system for doxorubicin (DOX), based on organic-inorganic composites was developed. DOX was incorporated in micelles (M-DOX) of polyethylene glycol-phosphatidylethanolamine (PEG-PE) which in turn were adsorbed by the clay, montmorillonite (MMT). The nano-structures of the PEG-PE/MMT composites of LOW and HIGH polymer loadings were characterized by XRD, TGA, FTIR, size (DLS) and zeta measurements. These measurements suggest that for the LOW composite a single layer of polymer intercalates in the clay platelets and the polymer only partially covers the external surface, while for the HIGH composite two layers of polymer intercalate and a bilayer may form on the external surface. These nanostructures have a direct effect on formulation stability and on the rate of DOX release. The release rate was reversely correlated with the degree of DOX interaction with the clay and followed the sequence: M-DOX>HIGH formulation>LOW formulation>DOX/MMT. Despite the slower release from the HIGH formulation, its cytotoxicity effect on sensitive cells was as high as the "free" DOX. Surprisingly, the LOW formulation, with the slowest release, demonstrated the highest cytotoxicity in the case of Adriamycin (ADR) resistant cells. Confocal microscopy images and association tests provided an insight into the contribution of formulation-cell interactions vs. the contribution of DOX release rate. Internalization of the formulations was suggested as a mechanism that increases DOX efficiency, particularly in the ADR resistant cell line. The employment of organic-inorganic hybrid materials as drug delivery systems, has not reached its full potential, however, its functionality as an efficient tunable release system was demonstrated. STATEMENT OF SIGNIFICANCE: DOX PEG-PE/clay formulations were design as an efficient drug delivery system. The main aim was to develop PEG-PE/clay formulations of different structures based on various PEG-PE/clay ratios in order to achieve tunable release rates, to control the external surface characteristics and formulation stability. The formulations showed significantly higher toxicity in comparison to "free" DOX, explained by formulation internalization. For each cell line tested, sensitive and ADR resistant, a different formulation structure was found most efficient. The potential of PEG-PE/clay-DOX formulations to improve DOX administration efficacy was demonstrated and should be further explored and implemented for other cancer drugs and cells.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clay-montmorillonite; Composites; Control released; DOX; PEG-PE

Mesh:

Substances:

Year:  2017        PMID: 28400314     DOI: 10.1016/j.actbio.2017.04.008

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  9 in total

Review 1.  A Review on Chitosan's Uses as Biomaterial: Tissue Engineering, Drug Delivery Systems and Cancer Treatment.

Authors:  Rayssa de Sousa Victor; Adillys Marcelo da Cunha Santos; Bianca Viana de Sousa; Gelmires de Araújo Neves; Lisiane Navarro de Lima Santana; Romualdo Rodrigues Menezes
Journal:  Materials (Basel)       Date:  2020-11-06       Impact factor: 3.623

2.  Micelles Loaded With Puerarin And Modified With Triphenylphosphonium Cation Possess Mitochondrial Targeting And Demonstrate Enhanced Protective Effect Against Isoprenaline-Induced H9c2 Cells Apoptosis.

Authors:  Wen-Qun Li; Jun-Yong Wu; Da-Xiong Xiang; Shi-Lin Luo; Xiong-Bin Hu; Tian-Tian Tang; Tao-Li Sun; Xin-Yi Liu
Journal:  Int J Nanomedicine       Date:  2019-10-21

3.  Supramolecular exfoliation of layer silicate clay by novel cationic pillar[5]arene intercalants.

Authors:  Takahiro Kakuta; Yudai Baba; Tada-Aki Yamagishi; Tomoki Ogoshi
Journal:  Sci Rep       Date:  2021-05-20       Impact factor: 4.379

4.  Innovative Linear Low Density Polyethylene Nanocomposite Films Reinforced with Organophilic Layered Double Hydroxides: Fabrication, Morphology and Enhanced Multifunctional Properties.

Authors:  Jiazhuo Xie; Haijun Wang; Zhou Wang; Qinghua Zhao; Yuechao Yang; Geoffrey I N Waterhouse; Lei Hao; Zihao Xiao; Jing Xu
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

5.  Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy.

Authors:  Juan Chen; Xiaobing Yang; Liuqing Huang; Huixian Lai; Chuanhai Gan; Xuetao Luo
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

6.  Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA.

Authors:  Guixiang Tian; Ruiyan Pan; Bo Zhang; Meihua Qu; Bo Lian; Hong Jiang; Zhiqin Gao; Jingliang Wu
Journal:  Front Pharmacol       Date:  2019-01-22       Impact factor: 5.810

7.  Clay Mineral Minerals as a Strategy for Biomolecule Incorporation: Amino Acids Approach.

Authors:  Luciano C Brandão-Lima; Fabrícia C Silva; Paulo V C G Costa; Edgar A Alves-Júnior; César Viseras; Josy A Osajima; Leilson R Bezerra; Jose F P de Moura; Aline G de A Silva; Maria G Fonseca; Edson C Silva-Filho
Journal:  Materials (Basel)       Date:  2021-12-22       Impact factor: 3.623

8.  Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile.

Authors:  Wenqun Li; Junyong Wu; Jiang Zhang; Jingjing Wang; Daxiong Xiang; Shilin Luo; Jianhe Li; Xinyi Liu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

9.  In Vivo and In Vitro Anticancer Activity of Doxorubicin-loaded DNA-AuNP Nanocarrier for the Ovarian Cancer Treatment.

Authors:  Chang-Seuk Lee; Tae Wan Kim; Da Eun Oh; Su Ok Bae; Jaesung Ryu; Hyejeong Kong; Hyeji Jeon; Hee Kyung Seo; Seob Jeon; Tae Hyun Kim
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.